Literature DB >> 33620284

Bilateral anterior segment dysgenesis and peripheral avascular retina with tractional retinal detachment in an infant with multiple congenital anomalies-hypotony-seizures syndrome 3.

Frances Wu1,2, Paula C Goldenberg3,4, Shizuo Mukai1,2.   

Abstract

Background: Multiple congenital anomalies-hypotony-seizures syndrome 3 (MCAHS3) is a rare autosomal recessive disorder caused by mutations in the PIGT gene. PIGT encodes phosphatidylinositol-glycan biosynthesis class T, which plays a crucial role in protein anchoring to cell membranes. The clinical presentation of MCAHS3 is variable in expression and severity, but can be characterized by developmental delay, seizures, hypotonia, facial dysmorphism, and other abnormalities.Materials and
Methods: Case report.
Results: We report unusual ocular findings including bilateral anterior segment dysgenesis, avascular retinal periphery, and tractional retinal detachment in a 1-month-old male infant with compound heterozygous PIGT mutations consistent with MCAHS3. Whole-exome sequencing did not detect any other genetic abnormalities.Conclusions: This case expands the clinical spectrum of MCAHS3 to include anomalies in ocular anterior segment and retinal vascular development. Given the rarity and the genetic heterogeneity of MCAHS3, giving rise to varied non-ocular phenotypes, it is possible that milder intraocular phenotypes could have gone unrecognized in the past.

Entities:  

Keywords:  MCAHS3; PIGT; genetics; pediatric; retina

Mesh:

Substances:

Year:  2021        PMID: 33620284     DOI: 10.1080/13816810.2021.1888133

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  1 in total

1.  Spectrum of Neurological Symptoms in Glycosylphosphatidylinositol Biosynthesis Defects: Systematic Review.

Authors:  Justyna Paprocka; Michał Hutny; Jagoda Hofman; Agnieszka Tokarska; Magdalena Kłaniewska; Krzysztof Szczałuba; Agnieszka Stembalska; Aleksandra Jezela-Stanek; Robert Śmigiel
Journal:  Front Neurol       Date:  2022-01-04       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.